Global Cell Culture Media Market Size & Outlook

Serum-free media was the largest segment with a revenue share of 36% in 2023. Horizon Databook has segmented the Global cell culture media market based on serum-free media, classical media, stem cell culture media, chemically defined media, specialty media, other cell culture media covering the revenue growth of each sub-segment from 2018 to 2030.

The biosimilars market is on the cusp of momentous growth. This growth is mainly due to the anticipated launch of several MAB biosimilars in the coming years as patents on significant drugs, such as trastuzumab (Herceptin from Roche), infliximab (Remicade from J& J), and Adalimumab (Humira from Abbott), are going to expire Emerging countries such as Venezuela, Brazil, Colombia, India, and Mexico have established regulations for biosimilar approval.

Russia is also developing a pathway for approval, as are other countries across Africa and Asia. The China FDA has also begun discussions on the development of a biosimilar approval procedure. Moreover, the reduction of manufacturing costs has become one of the most significant technological advantages for a biosimilar manufacturer. Therefore, the capability to imitate the biologically active molecule at the lowermost possible cost via cell culture has become important to efficient biosimilar development.